**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a single-centre retrospective cohort study of 65 patients, 2 patients \[*ages and sexes not stated*\] were described, who developed infection, and candidemia and invasive pulmonary aspergillosis following off label treatment with tocilizumab for COVID-19 pneumonia.

Both the patients had a history of COVID-19 pneumonia, for which they received off-label treatment with IV tocilizumab infusion 400mg along with hydroxychloroquine 400mg daily, azithromycin 500mg daily, lopinavir/ritonavir 400/100mg twice daily and ceftriaxone 2g for 6 days. Additionally, the patients received anti-coagulation prophylaxis with SC enoxaparin-sodium \[enoxaparin\] once a day. At day 13 of tocilizumab treatment, one patient who was in the medicine ward developed infection. Whereas, the other patient who in the ICU developed candidemia on day 18 and invasive pulmonary aspergillosis on day 22 \[*outcomes not stated*\].
